VYGR Live signals | Maximize Profits with Getagraph.com

SELL 104018 min ago

@ $7.28

Issued: 14 Feb 2024 @ 09:30

Return: 4.67%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.38 %

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Stats
Today's Volume	342 440
Average Volume	647 516
Market Cap	413.77M
EPS	$0 ( 2024-02-28 )
Next earnings date	( $-0.440 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	2.57
ATR14	$0.00700 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferguson Toby	Buy	105 000	Common Stock
2024-04-02	Swartz Robin	Sell	1 357	Common Stock
2024-04-02	Sandrock Alfred	Sell	12 115	Common Stock
2024-03-25	Ferguson Toby	Buy	210 000	Stock Option (Right to Buy)
2024-03-25	Ferguson Toby	Buy	0

INSIDER POWER
44.34
Last 94 transactions
Buy: 7 546 876 \| Sell: 3 757 926

Volume Correlation

Long: -0.07 (neutral)

Short: 0.93 (very strong)

Signal:(57.038) Expect same movement, but be aware

Voyager Therapeutics Inc Correlation

10 Most Positive Correlations
DYNT	0.929
DGLY	0.909
CRNC	0.909
ATNX	0.905
GFAI	0.905
LIVE	0.897
FTFT	0.896
ECOR	0.896
CFRX	0.889
APRE	0.886

10 Most Negative Correlations
MTEX	-0.862
ZENV	-0.859
VERA	-0.852
GRIN	-0.848
GRPH	-0.843
DSPC	-0.835
JAN	-0.832
RIVN	-0.831
LAWS	-0.827
VERX	-0.826

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Voyager Therapeutics Inc Correlation - Currency/Commodity

0.14
( neutral )

-0.03
( neutral )

0.00
( neutral )

-0.42
( neutral )

Voyager Therapeutics Inc Financials

Annual	2023
Revenue:	$250.01M
Gross Profit:	$245.57M (98.22 %)
EPS:	$3.08

FY	2023
Revenue:	$250.01M
Gross Profit:	$245.57M (98.22 %)
EPS:	$3.08

FY	2022
Revenue:	$40.91M
Gross Profit:	$34.72M (84.87 %)
EPS:	$-1.210

FY	2021
Revenue:	$37.42M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.890

Financial Reports:

No articles found.

Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.